De La Rosa Abel 4

What Happened

• Abel De La Rosa, a director of Dogwood Therapeutics, received a grant of 16,800 derivative shares (transaction code A) on June 16, 2026. The award is reported at $0.00 per share (no purchase price reported), indicating a compensation grant (e.g., restricted stock or RSUs) rather than an open-market purchase. The Form 4 was filed on June 17, 2026.

Key Details

• Transaction date: 2026-06-16; Form 4 filed: 2026-06-17 (timely filing).
• Reported price: $0.00 per share; reported shares acquired: 16,800 (derivative).
• Shares owned after transaction: not specified in the excerpt provided in this summary (check full Form 4 for total holdings).
• Transaction code: A (award/grant/acquisition of derivative security). No 10b5‑1 plan, tax withholding, or other footnotes were provided in the summary data shown.

Context

• A derivative award (often RSUs or restricted stock) typically vests over time and may be subject to transfer restrictions; it is a form of compensation intended to align director interests with shareholders. Such grants are common for board members and do not necessarily signal buying or selling intent. Check future filings for vesting events or subsequent sales.